India, April 4 -- India is unlikely to be significantly impacted by US President Donald Trump's announcement of 100 per cent tariffs on certain patented drugs, as the country primarily exports low-cost generic medicines to America, think tank GTRI said on Friday. Trump signed an executive order on April 2, announcing the imposition of a 100 per cent ad valorem duty rate on the import of certain patented pharmaceuticals and associated pharmaceutical ingredients.

The order, issued on April 2, 2026, builds on a Section 232 investigation launched on May 1, 2025, which cited national security risks from dependence on foreign drug supplies.

The Global Trade Research Initiative (GTRI) said the move has left "India largely protected, given its ...